Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.
Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, Coleman K, Christensen JG, Emerson EO, Jakowski A, Hook K, Los G, Moyer JD, Pruimboom-Brees I, Pustilnik L, Rossi AM, Steyn SJ, Su C, Tsaparikos K, Wishka D, Yoon K, Jakubczak JL. Jani JP, et al. Among authors: wishka d. Mol Cancer Ther. 2010 Apr;9(4):883-94. doi: 10.1158/1535-7163.MCT-09-0915. Epub 2010 Mar 30. Mol Cancer Ther. 2010. PMID: 20354118
F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd.
Morris J, Wishka DG, Lopez OD, Rudchenko V, Huang G, Hoffman SN, Borgel S, Georgius K, Carter J, Stotler H, Kunkel MW, Collins JM, Hollingshead MG, Teicher BA. Morris J, et al. Among authors: wishka dg. Mol Cancer Ther. 2021 Apr;20(4):625-631. doi: 10.1158/1535-7163.MCT-20-0738. Mol Cancer Ther. 2021. PMID: 33811149 Free PMC article.
Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.
Montgomery JI, Brown MF, Reilly U, Price LM, Abramite JA, Arcari J, Barham R, Che Y, Chen JM, Chung SW, Collantes EM, Desbonnet C, Doroski M, Doty J, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, McAllister L, McElroy E, Menard CA, Mitton-Fry M, Mullins L, Noe MC, O'Donnell J, Oliver R, Penzien J, Plummer M, Shanmugasundaram V, Thoma C, Tomaras AP, Uccello DP, Vaz A, Wishka DG. Montgomery JI, et al. Among authors: wishka dg. J Med Chem. 2012 Feb 23;55(4):1662-70. doi: 10.1021/jm2014875. Epub 2012 Feb 8. J Med Chem. 2012. PMID: 22257165
Potent inhibitors of LpxC for the treatment of Gram-negative infections.
Brown MF, Reilly U, Abramite JA, Arcari JT, Oliver R, Barham RA, Che Y, Chen JM, Collantes EM, Chung SW, Desbonnet C, Doty J, Doroski M, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, Marra A, McElroy E, Melnick M, Menard CA, Montgomery JI, Mullins L, Noe MC, O'Donnell J, Penzien J, Plummer MS, Price LM, Shanmugasundaram V, Thoma C, Uccello DP, Warmus JS, Wishka DG. Brown MF, et al. Among authors: wishka dg. J Med Chem. 2012 Jan 26;55(2):914-23. doi: 10.1021/jm2014748. Epub 2012 Jan 11. J Med Chem. 2012. PMID: 22175825
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.
Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN. Wishka DG, et al. J Med Chem. 2006 Jul 13;49(14):4425-36. doi: 10.1021/jm0602413. J Med Chem. 2006. PMID: 16821801
Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity.
Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, Myers JK, Wolfe ML, Groppi VE, Thornburgh BA, Tinholt PM, Walters RR, Olson BA, Fitzgerald L, Staton BA, Raub TJ, Krause M, Li KS, Hoffmann WE, Hajos M, Hurst RS, Walker DP. Acker BA, et al. Among authors: wishka dg. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3611-5. doi: 10.1016/j.bmcl.2008.04.070. Epub 2008 May 1. Bioorg Med Chem Lett. 2008. PMID: 18490160
The development of β-selective glycosylation reactions with benzyl substituted 2-deoxy-1,4-dithio-D-erythro-pentofuranosides: enabling practical multi-gram syntheses of 4'-Thio-2'-deoxycytidine (T-dCyd) and 5-aza-4'-thio-2'-deoxycytidine (aza-T-dCyd) to support clinical development.
Wishka DG, Lopez OD, Rudchenko VF, Huang G, Bahde R, Kumar V, Denysenko SM, Zhang L, Zhang M, Teicher BA, Morris J. Wishka DG, et al. Nucleosides Nucleotides Nucleic Acids. 2021;40(1):68-95. doi: 10.1080/15257770.2020.1832694. Epub 2020 Oct 16. Nucleosides Nucleotides Nucleic Acids. 2021. PMID: 33063584 Free article.
Synthesis of lipoxin B.
Morris J, Wishka DG. Morris J, et al. Among authors: wishka dg. Adv Prostaglandin Thromboxane Leukot Res. 1986;16:99-109. Adv Prostaglandin Thromboxane Leukot Res. 1986. PMID: 2949568 Review. No abstract available.
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
Barbachyn MR, Cleek GJ, Dolak LA, Garmon SA, Morris J, Seest EP, Thomas RC, Toops DS, Watt W, Wishka DG, Ford CW, Zurenko GE, Hamel JC, Schaadt RD, Stapert D, Yagi BH, Adams WJ, Friis JM, Slatter JG, Sams JP, Oien NL, Zaya MJ, Wienkers LC, Wynalda MA. Barbachyn MR, et al. Among authors: wishka dg. J Med Chem. 2003 Jan 16;46(2):284-302. doi: 10.1021/jm020248u. J Med Chem. 2003. PMID: 12519066
29 results